Mark your calendar. July 23 24. FDA advisory committee reviewing BPC 157, TB 500, MOTS C, semax, epitalon, KPV, and DSIP for the 503A compounding list. The peptide landscape could shift significantly. FDA Peptide Reclassification 2026: What Researchers Want FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with FDA Removes 12 Peptides from 503A Category 2 Newtropin